A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol

INTRODUCTION: The newer glucose-lowering therapies for type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonists (GLP1-RAs) and the sodium-glucose co-transporter 2 inhibitors (SGLT2i), have additional clinical benefits beyond improving glycaemic control; promoting weight loss, addressing...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Emily, Wilton, Moon M, Sprung, Victoria S, Harrold, Joanne A, Halford, Jason C G, Stancak, Andrej, Burgess, Malcolm, Howarth, Elaine, Umpleby, A Margot, Kemp, Graham J, Wilding, John PH, Cuthbertson, Daniel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292819/
https://www.ncbi.nlm.nih.gov/pubmed/34285005
http://dx.doi.org/10.1136/bmjopen-2020-045663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292819/
https://www.ncbi.nlm.nih.gov/pubmed/34285005
http://dx.doi.org/10.1136/bmjopen-2020-045663

Ejemplares similares